At the news
? NEUTRALIMPACT 3/10 8-K filed Apr 7, 2026 at 16:05 ET
Stoke Therapeutics appointed Dr. Clare Kahn, a seasoned biotech executive with deep regulatory and drug development expertise, to its board of directors. The move strengthens governance ahead of key Phase 3 data readouts for its lead candidate, zorevunersen, in Dravet syndrome.
- Dr. G. Clare Kahn, Ph.D., was appointed to Stoke's Board of Directors effective April 3, 2026.
- Dr. Kahn brings over three decades of industry experience, including senior roles at Pfizer, GSK, and X-VAX Technology Inc., with expertise in rare disease drug development and regulatory strategy.
- She was also appointed chairperson of the Research and Development Committee and to the Nominating and Corporate Governance Committee.
- The board size was increased to ten directors to accommodate the appointment.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access